Compare PPSI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | NXL |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | PPSI | NXL |
|---|---|---|
| Price | $4.08 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $5.00 |
| AVG Volume (30 Days) | 67.9K | ★ 109.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | ★ 36.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $31,751,000.00 | $156,931.00 |
| Revenue This Year | $26.84 | $38.28 |
| Revenue Next Year | $10.26 | $185.71 |
| P/E Ratio | $1.44 | ★ N/A |
| Revenue Growth | ★ 105.82 | N/A |
| 52 Week Low | $2.25 | $0.70 |
| 52 Week High | $6.19 | $4.19 |
| Indicator | PPSI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 37.05 |
| Support Level | $4.00 | $0.93 |
| Resistance Level | $4.24 | $1.01 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 75.02 | 6.76 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.